Consolidated Investment Group LLC Trims Stock Holdings in CVS Health Co. (NYSE:CVS)

Consolidated Investment Group LLC decreased its holdings in CVS Health Co. (NYSE:CVS) by 82.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,500 shares of the pharmacy operator’s stock after selling 52,500 shares during the quarter. Consolidated Investment Group LLC’s holdings in CVS Health were worth $908,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Live Oak Investment Partners purchased a new stake in shares of CVS Health in the fourth quarter valued at about $25,000. Atticus Wealth Management LLC grew its holdings in shares of CVS Health by 149.0% in the 4th quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after acquiring an additional 219 shares during the period. Cornerstone Planning Group LLC increased its stake in CVS Health by 111.5% in the 3rd quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 243 shares in the last quarter. PCA Investment Advisory Services Inc. purchased a new stake in CVS Health during the second quarter worth $37,000. Finally, ZRC Wealth Management LLC increased its position in shares of CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 0.4 %

CVS stock opened at $79.76 on Friday. CVS Health Co. has a 52-week low of $64.41 and a 52-week high of $83.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. The firm has a market capitalization of $100.37 billion, a P/E ratio of 12.35, a P/E/G ratio of 1.05 and a beta of 0.51. The company’s 50 day simple moving average is $75.66 and its 200-day simple moving average is $73.46.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.11. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The company had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. During the same quarter in the previous year, the business posted $1.99 EPS. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, equities research analysts anticipate that CVS Health Co. will post 8.33 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Friday, April 19th. This represents a $2.66 annualized dividend and a dividend yield of 3.34%. CVS Health’s dividend payout ratio is 41.18%.

Insider Activity at CVS Health

In other news, EVP Prem S. Shah sold 29,473 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.25% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on CVS. Royal Bank of Canada decreased their price objective on CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a research note on Thursday, February 8th. SVB Leerink began coverage on shares of CVS Health in a report on Monday, February 26th. They issued an “outperform” rating and a $88.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $87.00 target price on shares of CVS Health in a research note on Thursday, February 8th. TD Cowen lowered their price objective on CVS Health from $102.00 to $99.00 and set an “outperform” rating for the company in a research note on Monday, December 11th. Finally, Barclays began coverage on shares of CVS Health in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 price target on the stock. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $90.21.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.